1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate

Raises Hopes Of Challenging Abecma And Carvykti

 
• By Andrew McConaghie

While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.

Allogene building
Allogene's CD19-targeting off-the-shelf CAR-Ts have hit setbacks, putting pressure on its multiple myeloma targeting candidates to succeed. • Source: Alamy

Allogene Therapeutics has repeatedly stumbled in its efforts to develop the first off-the-shelf CAR-T therapy for B-cell lymphoma, but is now touting preclinical data suggesting its platform could produce a more effective product than already-marketed autologous multiple myeloma CAR-Ts.

That is significant as its lead candidate, ALLO-501A, has yet to demonstrate durable efficacy to match the established autologous CAR-Ts...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.